Corneal Melt in Collagen Vascular Disease

A corneal melt occurring in the context of an underlying collagen vascular disease is one of the clearest examples in ophthalmology of an eye finding that signals a life-threatening systemic problem, since progressive stromal thinning in this setting usually reflects active vasculitis, and treating the cornea alone without addressing the systemic disease is a well-documented path to both corneal perforation and, in severe cases, patient mortality.

Clinical eye photograph illustrating Corneal Melt Collagen Vascular Disease

Why Collagen Vascular Disease Causes Corneal Melting

The peripheral cornea is nourished in part by the limbal vascular arcade, and immune complex deposition and vasculitis affecting these vessels, along with local release of destructive enzymes including collagenases from inflammatory cells, leads to progressive breakdown of the corneal stroma.

This process, most classically seen as peripheral ulcerative keratitis, can also occur centrally and can progress rapidly from mild thinning to frank perforation if the underlying systemic inflammation is not controlled.

Associated Systemic Diseases

Rheumatoid arthritis, the most common association, particularly in long-standing, seropositive, and erosive disease
Granulomatosis with polyangiitis, in which corneal melt can be an early or presenting sign of active systemic vasculitis
Relapsing polychondritis
Systemic lupus erythematosus
Polyarteritis nodosa and other systemic vasculitides
Less commonly, inflammatory bowel disease and other autoimmune conditions

A corneal melt in a patient with known rheumatoid arthritis, particularly if the arthritis has been poorly controlled or has flared, should be treated as a marker of active systemic vasculitis until proven otherwise.

Clinical Presentation

Progressive thinning of the corneal stroma, often peripheral but occasionally central
Pain, redness, and photophobia, though pain can be relatively mild given the severity of tissue destruction in some cases
Crescentic guttering or ulceration at the limbus in peripheral ulcerative keratitis
Risk of perforation if thinning progresses unchecked, sometimes over a period of days
The sclera adjacent to the cornea may also show scleritis in the same eye, reflecting the shared vasculitic process

Differential Diagnosis

Infectious keratitis, which must be excluded with culture, since immunosuppression is the treatment for the vasculitic process but would be harmful if an active infection were missed
Mooren ulcer, a related but idiopathic form of peripheral ulcerative keratitis without an identified systemic association, requiring its own workup to confirm the absence of systemic disease before that diagnosis is accepted
Neurotrophic keratopathy, which causes stromal thinning through a different mechanism, related to loss of corneal sensation rather than vasculitis
Terrien marginal degeneration, a slowly progressive, typically painless and non-inflammatory peripheral thinning, distinguished by its different clinical course

Workup

A full systemic vasculitis and autoimmune disease screen, mirroring the workup for scleritis: rheumatoid factor, anti-CCP antibodies, ANCA, ANA, complement levels, and inflammatory markers
Corneal culture to exclude a superimposed or alternative infectious cause before starting systemic immunosuppression
Coordination with rheumatology, both to confirm or characterize the underlying systemic disease and to manage systemic treatment

Management

Systemic Immunosuppression

This is the central and most important treatment, since corneal melt in this setting represents a manifestation of systemic vasculitis; treating the eye alone, without adequate systemic immunosuppression, has a well-documented history of poor outcomes, including recurrent melting and death from uncontrolled systemic vasculitis.

Systemic corticosteroids are used for initial control, followed by steroid-sparing agents such as cyclophosphamide, rituximab, or other immunosuppressants depending on the specific underlying disease, chosen and managed by rheumatology.

Local Ocular Measures

Lubrication and, in severe cases, a bandage contact lens or tarsorrhaphy to protect a severely thinned cornea
Topical collagenase inhibitors, such as topical medroxyprogesterone or doxycycline given systemically, sometimes used as adjuncts, though systemic immunosuppression remains the primary treatment
Topical corticosteroids are used cautiously, since they can theoretically worsen stromal thinning if collagen synthesis is also being suppressed, and their use is balanced against the inflammatory component

Surgical Management

Impending or actual perforation may require tissue glue, an amniotic membrane patch, a corneal or scleral patch graft, or in severe cases a therapeutic penetrating keratoplasty, performed alongside, not instead of, systemic immunosuppression.

Prognosis

Ocular and systemic outcomes have improved substantially with prompt recognition and modern immunosuppressive therapy, but corneal melt in the setting of collagen vascular disease remains a marker of serious disease activity that requires urgent, coordinated ophthalmic and rheumatologic care.

References

Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Ophthalmology. 1984;91:1253-1263.
Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol. 1999;43:379-396.
Tauber J, Sainz de la Maza M, Hoang-Xuan T, Foster CS. An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis. Cornea. 1990;9:66-73.
Gomes JA, Rodrigues PC, Lopes LN. Mooren’s ulcer and infectious peripheral ulcerative keratitis. Semin Ophthalmol. 2014;29:327-337.

Corneal Melt in Collagen Vascular Disease: A Cornea Reflecting a Systemic Storm